Vemurafenib (Zelboraf) for BRAF V600 mutation positive melanoma; completely resected but at high risk of recurrence

Vemurafenib is a drug targeting a specific gene mutation (called BRAF V600) seen in some melanomas. Melanoma is a type of skin cancer. Vemurafenib is a type of cancer treatment called a cancer growth blocker. The gene mutation (BRAF V600) seen in some melanomas leads to the production of a mutated (BRAF) protein, by blocking the mutated protein the treatment stops the melanoma cells from growing and dividing.Vemurafenib is given orally as a tablet. It is already licenced for certain melanoma patients, but is currently being trialled as a new treatment option for patients who have had surgery but are at high risk of their melanoma returning. Vemurafenib could potentially improve the survival time of these patients.